The 19 most recent market catalysts affecting $EBS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 16, 2026
Corporate Catalyst
Bullish
Impact 55
Asimov and Emergent BioSolutions Announce Cell Line Development Partnership
Emergent BioSolutions announced a strategic partnership with Asimov for cell line development of two monoclonal antibodies targeting Ebola. This collaboration is significant as it …
Nov 6, 2026
Corporate Catalyst
Bullish
Impact 55
Erste Group and Erste Bank Polska Invest in Innovate PL FoF
Erste Group Bank AG and its subsidiary Erste Bank Polska S.A. are participating in the Innovate PL FoF program, which aims to provide capital to private equity, private debt, and v…
Nov 5, 2026
Corporate Catalyst
Neutral
Impact 55
Erste Bank Polska S.A. Announces Tier II Bond Issuance
Erste Bank Polska S.A. has announced the issuance of Tier II bonds, a standard capital management tool for banks. This event is significant as it occurs after the bank's rebranding…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 55
Emergent BioSolutions Receives $22.3 Million Anthrax Vaccine Contract Modification
Emergent BioSolutions announced a contract modification worth up to $22.3 million from the Pentagon for its BioThrax anthrax vaccine. This is an exercise of an option period under …
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 65
Baader Bank Analysts Upgrade Erste Group to 'Add'
Baader Bank analysts, led by David Grinsztajn, upgraded Erste Group Bank AG's rating from 'Reduce' to 'Add', setting a 6-month price target of 128 euros. This upgrade is significan…
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 55
Emergent BioSolutions Reports Third Quarter 2026 Financial Results
Emergent BioSolutions announced its third-quarter 2026 financial results, reporting revenue of $110.0 million, which was consistent with the company's previously issued guidance. T…
Oct 30, 2026
Corporate Catalyst
Bullish
Impact 65
Erste Group Receives Regulatory Approval for Erste Bank Polska Tender Offer
Erste Group has secured regulatory approval for a voluntary tender offer to acquire a larger stake in its Polish subsidiary, Erste Bank Polska. This is a significant step towards c…
Oct 16, 2026
Corporate Catalyst
Bearish
Impact 65
Emergent BioSolutions shares are trading lower. The company announced its CFO Richard Lindahl will retire, with Treasurer Frank Vargo set to serve as interim CFO effective January 1, 2027.
The retirement of a CFO, especially from a company like Emergent BioSolutions which has faced recent operational challenges, can be viewed negatively by investors. It raises questi…
Oct 16, 2026
Corporate Catalyst
Neutral
Impact 65
Emergent Biosolutions Appoints Treasurer Frank Vargo As Interim CFO, Effective Jan. 1, 2027, Succeeding Richard Lindahl
Emergent BioSolutions is undergoing a change in its financial leadership, with Frank Vargo stepping in as Interim CFO on January 1, 2027, following Richard Lindahl's departure. Thi…
Sep 9, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Emergent BioSolutions, Maintains $10 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Emergent BioSolutions (EBS) and maintained a $10 price target. This i…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 60
Emergent BioSolutions Receives ~$24M Contract Modification From Biomedical Advanced Research And Development Authority For Strategic Preparedness Response Within U.S. Department Of Health And Human Services To Provide CYFENDUS
Emergent BioSolutions announced a $24 million contract modification from BARDA to supply CYFENDUS, an anthrax vaccine. This is a positive development for EBS as it represents a con…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 65
Emergent BioSolutions Receives Canada's Offer To Provide NARCAN Nasal Spray, Effective Oct. 1 Through September 2029
Emergent BioSolutions (EBS) announced it won a competitive bid to supply NARCAN Nasal Spray to the Government of Canada. This is a positive development for EBS as it secures a sign…
Aug 21, 2026
Corporate Catalyst
Neutral
Impact 65
JP Morgan Reinstates Underweight on Emergent BioSolutions
JP Morgan analyst Jessica Fye has reinstated an 'Underweight' rating on Emergent BioSolutions (EBS). This action signals a negative outlook from a prominent financial institution, …
Aug 10, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10
HC Wainwright & Co. analyst Raghuram Selvaraju has adjusted the price target for Emergent BioSolutions (EBS) from $12 to $10, while reiterating a 'Buy' rating. This action signals …
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Emergent BioSolutions shares are trading lower after the company lowered its FY2026 sales guidance.
This headline represents a significant corporate catalyst for Emergent BioSolutions (EBS). Lowering long-term sales guidance directly impacts investor perception of future profitab…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 85
Emergent BioSolutions shares are trading lower after the company lowered its FY2026 sales guidance.
The lowered FY2026 sales guidance for Emergent BioSolutions (EBS) is a significant negative catalyst, directly impacting the company's future revenue expectations and profitability…
Aug 5, 2026
Corporate Catalyst
Neutral
Impact 95
Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
Emergent BioSolutions (EBS) announced a drastic reduction in its Q3 sales forecast, now expecting $110 million-$130 million, which is considerably below the $209 million analyst co…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est
Emergent BioSolutions (EBS) has announced a substantial reduction in its sales outlook for fiscal year 2026, moving from a range of $720 million-$760 million down to $645 million-$…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 85
Emergent BioSolutions Q2 Adj. EPS $0.60 Beats $0.11 Estimate, Sales $234.300M Beat $177.500M Estimate
This headline is a significant corporate catalyst for Emergent BioSolutions (EBS). The substantial beat on both adjusted EPS and sales indicates that the company is performing much…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.